ACE-031 is an experimental recombinant fusion protein based on the extracellular domain of activin receptor type IIB (ACVR2B) linked to an IgG1 Fc region. It has been studied as a soluble receptor or ligand trap for investigating myostatin and related signaling pathways.

ACE-031 is more accurately described as a recombinant fusion protein rather than a conventional short peptide. Its structure contains an ACVR2B-derived extracellular receptor domain fused to an IgG1 Fc domain.

ACVR2B stands for activin receptor type-2B, also known as activin receptor type IIB (ActRIIB). It is a cell-surface receptor involved in signaling by several members of the transforming growth factor beta (TGF-β) superfamily.

No. ACE-031 is a soluble fusion protein derived from the extracellular portion of ACVR2B. ACVR2B itself is a naturally occurring receptor protein that participates in cellular signaling.

ACE-031 uses the ligand-binding extracellular domain of ACVR2B as part of its molecular structure. This allows ACE-031 to function as a soluble receptor-like molecule in experimental systems.

ACE-031 acts as a soluble receptor-like ligand trap. Its ACVR2B-derived extracellular domain can bind selected ligands that would otherwise interact with endogenous receptors.

Myostatin normally contributes to signaling that limits skeletal muscle growth. Studying its interaction with soluble ACVR2B-based molecules helps researchers investigate mechanisms controlling muscle mass.

Researchers may consider identity, purity, concentration, protein integrity, aggregation profile, endotoxin status where relevant, and supporting analytical documentation.

Depending on the supplier and analytical program, a COA may include batch identification, protein identity, purity, concentration, appearance, testing methods, and other quality-control results.

SDS-PAGE can help evaluate apparent molecular size and identify major and minor protein species.

Mass spectrometry can provide molecular-level information that supports identity and structural characterization.

No. Purity and biological activity are separate analytical characteristics. A highly pure protein may still require a suitable functional assay to confirm activity.

Repeated temperature cycling can potentially affect protein stability. Researchers should follow the validated storage instructions supplied with the specific material.

Excessive heat can adversely affect recombinant protein structure and stability. ACE-031 should therefore be handled according to appropriate protein-storage procedures.

Repeated freeze-thaw cycles can potentially cause aggregation or structural changes in recombinant proteins. Researchers should use validated handling procedures designed to minimize unnecessary cycling.

ACE-031 is an experimental molecule and should be treated as research material rather than an approved pharmaceutical product.

ACE-031 and ACE-083 are related experimental approaches to modulating myostatin/activin signaling, but their molecular designs and biological targeting characteristics differ.

No. ACE-031 is a soluble receptor-Fc fusion protein, while a myostatin antibody is an immunoglobulin-based molecule designed to recognize a specific target antigen.

ACE-031 has also been referred to as ramatercept. Scientific literature commonly describes it as an ACVR2B-Fc fusion protein.

ACE-031 was developed during research into therapeutics targeting muscle-regulating pathways, including work associated with Acceleron Pharma.

ACE-031 remains of scientific interest as an experimental tool for studying ACVR2B-mediated signaling, myostatin biology, muscle regulation, and related TGF-β superfamily pathways.

Research involving ACE-031 can investigate ligand trapping, myostatin signaling, muscle biology, skeletal muscle development, and interactions among ACVR2B-related pathways.

Myostatin, also known as growth differentiation factor 8 (GDF-8), is one of the principal signaling proteins investigated in connection with ACE-031.

Myostatin is a member of the TGF-β superfamily that functions as an important negative regulator of skeletal muscle growth.

GDF-8, or growth differentiation factor 8, is the scientific name for myostatin. The terms myostatin and GDF-8 therefore refer to the same signaling protein.

A Certificate of Analysis (COA) is documentation summarizing analytical test results for a specific batch of research material.

Chromatographic analysis can help assess purity and related components, although recombinant fusion proteins may require multiple complementary analytical techniques.

Like other recombinant proteins, ACE-031 can potentially form aggregates under unfavorable conditions. Aggregation is therefore an important consideration in protein characterization and storage.

Storage conditions should follow the supplier’s batch-specific documentation and validated handling instructions. Recombinant proteins generally require controlled conditions to preserve structural integrity.

Whether freezing is appropriate depends on the formulation and validated stability information for the specific research material. The product’s technical documentation should take precedence.

Aseptic handling helps minimize microbial contamination and supports the integrity of laboratory experiments.

Yes. Buffer composition, concentration, pH, excipients, temperature, and container conditions can all influence recombinant-protein stability.

Yes. Recombinant research proteins should be handled by appropriately trained personnel using suitable laboratory procedures.

Batch numbers allow experimental results to be traced to a specific material and support reproducibility, quality control, and documentation.

No. ACE-031 is an ACVR2B-Fc fusion protein, whereas follistatin is a naturally occurring secreted glycoprotein that binds several members of the TGF-β superfamily.

ACE-031 Clinical Trials and Safety Concerns

Clinical development of ACE-031 (ramatercept) was discontinued after clinical trials identified vascular and bleeding-related adverse events. Reported events included nosebleeds, gum bleeding, and the development of telangiectasias (dilated small blood vessels in the skin).

Documented Adverse Events

• Nosebleeds (Epistaxis): Nosebleeds were reported among participants in clinical studies.
• Gum Bleeding (Gingival Bleeding): Bleeding involving the gums and other mucosal tissues was also reported.
• Dilated Blood Vessels (Telangiectasias): Participants developed visible, small dilated blood vessels near the surface of the skin.
• Injection-Site Reactions: Local reactions such as redness (erythema) and swelling were reported in some participants.

Why Were ACE-031 Trials Discontinued?

ACE-031 is an ACVR2B-Fc fusion protein that can bind multiple ligands involved in the activin and myostatin signaling pathways. Its activity was not limited to myostatin. Broader ligand binding was investigated as a potential explanation for some of the observed vascular effects, including interactions with signaling pathways involving BMP9 and BMP10, which are important for vascular biology.

Because of these safety concerns, further clinical development of ACE-031 was discontinued by its developers.

Important Research Note

ACE-031 is an experimental research molecule and is not an approved human therapeutic. The information above summarizes findings reported from clinical research and should not be interpreted as evidence that ACE-031 is safe or effective for treating any medical condition.

Safety of Myostatin Inhibitors

The long-term safety profile of myostatin inhibitors remains uncertain. Although clinical studies of investigational myostatin- or activin-pathway inhibitors have provided useful information about their potential effects in specific muscle-related conditions, these compounds remain under investigation and should not be considered established treatments for general use or athletic enhancement.

Clinical Research Status

• Under Investigation: Myostatin and activin-pathway inhibitors have been investigated for conditions involving muscle loss or impaired muscle function, including muscular dystrophy, spinal muscular atrophy, and sarcopenia.
• Not Generally Approved: No myostatin-inhibiting drug is currently approved for general muscle enhancement or athletic performance.
• Sports Regulations: Certain myostatin-pathway agents are prohibited under applicable World Anti-Doping Agency (WADA) regulations. Athletes should always consult the current WADA Prohibited List.

Potential Risks and Safety Considerations

• Musculoskeletal Effects: Changes in muscle mass or muscle function may alter mechanical loading on tendons, joints, and other connective tissues. The clinical significance of these effects depends on the specific compound and research setting.
• Off-Target Signaling: Some ACVR2B-based or broader pathway inhibitors can interact with multiple members of the TGF-β superfamily rather than selectively blocking myostatin. This broader activity may contribute to unintended biological effects, including vascular or bleeding-related effects observed with certain investigational compounds.
• Product Quality: Unapproved peptides, recombinant proteins, or other compounds purchased from unverified online sources may have uncertain identity, purity, potency, sterility, and stability. Products marketed under names such as follistatin variants or myostatin inhibitors may not contain the stated compound.
• Limited Long-Term Data: Because many myostatin-pathway compounds remain investigational, their long-term safety and effects across different populations have not been fully established.

ACE-031 Specific Consideration

ACE-031 is an experimental ACVR2B-Fc fusion protein whose clinical development was discontinued following vascular and bleeding-related safety concerns. These findings demonstrate why broader ACVR2B ligand trapping should not be considered equivalent to selective myostatin inhibition.

ACE-031 is not an approved human therapeutic and is intended for research purposes only.

No. ACVR2B-based ligand traps can interact with multiple members of the TGF-β superfamily. Consequently, ACE-031 research is broader than myostatin alone.

Research may examine activin-related signaling and other ligands capable of interacting with ACVR2B or related receptors.

ACE-031 is not considered completely myostatin-specific. Its ACVR2B-derived binding domain can interact with multiple ligands, which is important when interpreting experimental results.

Ligand trapping describes the use of a soluble binding molecule to capture signaling proteins before they interact with their normal cell-surface receptors.

An ACVR2B ligand trap is a soluble form of the receptor’s extracellular binding region designed to interact with extracellular signaling molecules.

ACE-031 is designed as an extracellular soluble protein. Its principal mechanism involves binding extracellular ligands rather than functioning as a conventional intracellular signaling molecule.

ACE-031 is designed as an extracellular soluble protein. Its principal mechanism involves binding extracellular ligands rather than functioning as a conventional intracellular signaling molecule.

The recombinant ACVR2B-Fc structure contains potential glycosylation sites, and glycosylation can influence the molecular mass and biochemical characteristics of recombinant proteins.

Yes. As a recombinant extracellular-domain/Fc fusion protein, ACE-031 contains disulfide bonds that contribute to its three-dimensional structure and dimeric architecture.

The ACVR2B portion corresponds to the extracellular ligand-binding region of activin receptor type IIB.

The Fc portion is derived from human IgG1 and is fused to the receptor domain as part of the recombinant protein design.

No. Luspatercept is a different therapeutic fusion protein based on an activin receptor type IIB extracellular domain fused to an IgG1 Fc domain and has distinct ligand-binding and clinical characteristics.

No. Different myostatin-pathway research compounds act at different points in the signaling network. ACE-031 functions primarily through soluble receptor-mediated ligand trapping.

Researchers should consult peer-reviewed scientific literature, clinical-trial records, validated analytical documentation, and authoritative scientific databases. ACE-031 should be treated as an experimental research molecule, not an approved human therapeutic.

ACE-031 is not intended to function like a conventional membrane-bound ACVR2B receptor. Instead, the soluble receptor domain is used to bind relevant extracellular ligands.

Reducing myostatin signaling can alter pathways associated with skeletal muscle growth and differentiation. The precise biological response depends on the experimental model and the degree of pathway modulation.

No. ACE-031 is a recombinant fusion protein and should not be classified as a conventional steroid or peptide hormone.

ACE-031 consists of an extracellular ACVR2B-derived receptor domain connected through a linker region to an IgG1 Fc domain.

The Fc region is used as a protein-engineering component that can support dimerization and influence the pharmacokinetic properties of the fusion protein.

ACE-031 is described as a dimeric ACVR2B-Fc fusion protein.

The molecular mass depends on the exact molecular form, glycosylation, and analytical conditions. Because ACE-031 is a glycoprotein fusion protein, its experimentally observed molecular mass can differ from a simple theoretical amino-acid calculation.

Full-length ACVR2B is a membrane-associated receptor containing extracellular, transmembrane, and intracellular regions. ACE-031 is a soluble engineered fusion protein based primarily on the extracellular receptor domain and an Fc region.

Yes. Proper analytical characterization can distinguish an ACVR2B-Fc fusion protein from full-length ACVR2B using techniques such as SDS-PAGE, immunoblotting, mass spectrometry, and other protein-characterization methods.

ACE-031 is itself a soluble engineered ACVR2B-based receptor fusion. The addition of an Fc domain distinguishes it structurally from a simple soluble receptor fragment.

No. Bimagrumab is a monoclonal antibody targeting activin type II receptors, whereas ACE-031 is a soluble ACVR2B-Fc fusion protein.

Because materials marketed under similar names may contain different proteins. Independent analytical verification is important when evaluating the identity and quality of research material.

Identity can be investigated using complementary analytical methods such as immunoblotting, SDS-PAGE, mass spectrometry, chromatographic analysis, and appropriate protein-specific assays.

Protein characterization helps verify molecular identity, purity, integrity, aggregation state, and consistency of a research material.

Potential techniques include SDS-PAGE, Western blotting, size-exclusion chromatography, mass spectrometry, peptide mapping, and other protein analytical methods.

Chromatographic methods can contribute to protein characterization, although a complete analytical profile for a recombinant fusion protein generally requires more than a single chromatographic measurement.

Yes. Mass spectrometry can help investigate molecular identity, sequence-related characteristics, molecular mass, and protein composition.

SDS-PAGE can provide information about apparent molecular size, protein integrity, and the presence of additional protein species.

ACE-031 has been investigated as a tool for studying mechanisms that regulate skeletal muscle mass and muscle-related signaling.

Yes. Its interaction with the ACVR2B/myostatin signaling system makes it useful as an experimental research tool for studying myostatin biology.

ACE-031 can be investigated in appropriately designed in-vitro systems to study extracellular ligand interactions and downstream signaling.

Experimental ACVR2B pathway research may use appropriate animal models to investigate systemic biological effects. Such work must follow applicable institutional and regulatory requirements.

Yes. Skeletal muscle biology is one of the major areas in which ACVR2B/myostatin signaling has been investigated.

Researchers have investigated myostatin and ACVR2B signaling in the context of muscle wasting and muscle-maintenance biology.

Clinical development was discontinued after safety concerns emerged, including vascular-related adverse effects such as telangiectasia and nosebleeds.

ACE-031 should not be presented as an established safe human-use product. It is not an approved pharmaceutical, and its clinical development was discontinued.

ACE-031 should not be represented as an approved treatment for muscular dystrophy. Its investigation in muscular dystrophy was experimental, and clinical development was discontinued.

No established therapeutic indication exists for ACE-031.

ACE-031 affects signaling pathways involving multiple ligands. Consequently, experimental findings may involve biological effects beyond direct myostatin inhibition.

No. Results from animal or cellular studies cannot automatically be translated into human therapeutic outcomes.

ACE-031 should not be promoted for self-experimentation or unsupervised human use. Research materials should be handled by appropriately qualified personnel under applicable laboratory procedures.

Recombinant proteins can be sensitive to aggregation, degradation, contamination, and structural changes. Consistent quality is therefore important for reproducible research.

ACE-031 was investigated clinically in the context of Duchenne muscular dystrophy research. Its development was ultimately discontinued.

Yes. Because ACVR2B interacts with several TGF-β superfamily ligands, ACE-031 can be relevant to experimental studies involving activin-related signaling.

Research into ACVR2B and related ligands has examined effects beyond muscle, including aspects of adipose biology and metabolic regulation.

Yes. ACE-031 can serve as a molecular tool for investigating ligand-receptor interactions and TGF-β superfamily signaling.

Yes. Its soluble receptor architecture makes ACE-031 relevant to experimental studies of extracellular ligand binding.

Yes. Researchers can investigate its interactions with relevant extracellular signaling proteins using suitable biochemical assays.

Yes. ACE-031 is particularly relevant to research involving ACVR2B-associated members of the TGF-β superfamily.

Yes. ACE-031 can be compared with other receptor-Fc fusion proteins, myostatin-targeting molecules, or related signaling modulators in controlled experimental studies.

Yes. ACE-031 was investigated in clinical studies before its development was discontinued.

Telangiectasia refers to visibly dilated small blood vessels near the surface of the skin or mucous membranes.

Yes. Vascular-related effects were among the important safety findings associated with clinical development of ACE-031.

No. ACE-031 is not an FDA-approved drug.

ACE-031 is not an approved pharmaceutical medicine in Europe.

There is no approved clinical indication for ACE-031 to treat muscle wasting. Research into the pathway does not establish ACE-031 as a therapeutic treatment.

Clinical investigation identified safety concerns, particularly vascular effects. Because ACE-031 is not an approved therapy, it should not be presented as having an established human safety profile.

No. ACE-031 is an experimental research molecule rather than an approved medical treatment.

Research-use-only means the material is supplied for laboratory investigation and is not represented as a product intended for human or veterinary diagnosis, treatment, or consumption.

ACE-031 Effects, Clinical Findings, and Safety

ACE-031 is an experimental ACVR2B-Fc fusion protein investigated for its ability to modulate myostatin and related signaling pathways involved in muscle regulation. Early clinical research demonstrated changes in lean body mass and body composition; however, clinical development was discontinued after vascular and bleeding-related safety concernsemerged.

ACE-031 is not an approved pharmaceutical or dietary supplement and should not be considered an established treatment for muscle growth, fat loss, or athletic enhancement.

Clinical Findings

• Lean Body Mass: Early clinical studies reported increases in lean body mass following ACE-031 administration. The magnitude of these changes varied according to the study design, dose, and assessment period.
• Body Composition: Clinical research investigated changes in lean mass and fat mass as part of the overall assessment of ACE-031’s biological effects.
• Muscle-Related Research: ACE-031 was investigated in conditions involving impaired muscle growth or muscle loss, including research involving Duchenne muscular dystrophy.

Safety and Risks

• Vascular Effects: ACE-031 interacts with multiple ligands in the activin/myostatin signaling network rather than selectively targeting myostatin alone. This broader activity was associated with vascular-related safety concerns during clinical development.
• Bleeding-Related Effects: Clinical studies reported adverse events including epistaxis (nosebleeds), gingival bleeding, and telangiectasias (visible dilated blood vessels).
• Clinical Development Discontinued: Because of these safety concerns, further clinical development of ACE-031 was discontinued.
• Regulatory Status: ACE-031 is not an approved human therapeutic. It should not be presented as a supplement, performance-enhancing product, or established treatment.
• Research Material Quality: ACE-031 or other experimental proteins obtained from unverified sources may have uncertain identity, purity, concentration, stability, or biological activity. Appropriate analytical documentation and independent characterization are important when evaluating research materials.

Important Research Note

The effects observed in clinical or preclinical studies should not be interpreted as evidence that ACE-031 is safe or effective for muscle growth, fat reduction, or other non-approved uses. ACE-031 remains an experimental research molecule, and its clinical development was discontinued because of safety concerns.

ACE-031 is an investigational therapeutic fusion protein designed to build muscle mass by blocking myostatin and other proteins that limit muscle growth. Although early trials showed rapid increases in lean muscle and bone volume, clinical development was halted due to vascular side effects like nosebleeds and small blood vessel dilation.